177 related articles for article (PubMed ID: 17449210)
21. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL
Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.
Johnson AP; Lamagni TL; Wale M; Cavendish S; Bishop L; Alhaddad N; Warner M; Livermore DM; Duckworth G; George RC
Int J Antimicrob Agents; 2005 Jun; 25(6):539-41. PubMed ID: 15890501
[TBL] [Abstract][Full Text] [Related]
23. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
Hovde LB; Simonson DA; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Mar; 60(3):295-9. PubMed ID: 18053674
[TBL] [Abstract][Full Text] [Related]
24. Serum bactericidal activity of levofloxacin against Streptococcus pneumoniae.
Shah PM
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():61-5. PubMed ID: 10404340
[TBL] [Abstract][Full Text] [Related]
25. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
Smith HJ; Noreddin AM; Siemens CG; Schurek KN; Greisman J; Hoban CJ; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2004 Sep; 48(9):3630-5. PubMed ID: 15328145
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
[TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
[TBL] [Abstract][Full Text] [Related]
29. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci.
Flatz L; Cottagnoud M; Kühn F; Entenza J; Stucki A; Cottagnoud P
J Antimicrob Chemother; 2004 Feb; 53(2):305-10. PubMed ID: 14729741
[TBL] [Abstract][Full Text] [Related]
30. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli.
Stein GE; Schooley SL; Nicolau DP
Int J Antimicrob Agents; 2008 Oct; 32(4):320-5. PubMed ID: 18715762
[TBL] [Abstract][Full Text] [Related]
31. parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
Sun HK; Du X; DeRyke CA; Doern GV; Nicolau DP
Int J Antimicrob Agents; 2007 Feb; 29(2):230-2. PubMed ID: 17204405
[No Abstract] [Full Text] [Related]
32. Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
Dalhoff A; Krasemann C; Wegener S; Tillotson G
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S22-9. PubMed ID: 11249825
[TBL] [Abstract][Full Text] [Related]
33. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Black J; Moland ES; Chartrand SA; Thomson KS
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189
[TBL] [Abstract][Full Text] [Related]
34. Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.
Nguyen HA; Grellet J; Dubois V; Saux MC; Quentin C
J Antimicrob Chemother; 2007 Apr; 59(4):755-8. PubMed ID: 17353222
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Elshafie SS; Al-Kuwari J
Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
[No Abstract] [Full Text] [Related]
36. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone.
Ozyuncu O; Nemutlu E; Katlan D; Kir S; Beksac MS
Int J Antimicrob Agents; 2010 Aug; 36(2):175-8. PubMed ID: 20418070
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
[TBL] [Abstract][Full Text] [Related]
38. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M
Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration.
Fernández-Varón E; Bovaira MJ; Espuny A; Escudero E; Vancraeynest D; Cárceles CM
J Vet Pharmacol Ther; 2005 Aug; 28(4):343-8. PubMed ID: 16050813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
